文献速递肾小球疾病肾移植

抗CD38单克隆抗体在肾脏疾病中的应用:机制原理与新出现的临床证据

Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-15

本文为叙述性综述,总结表达CD38的免疫细胞在肾脏疾病中的病理生理作用,并批判性评估抗CD38单克隆抗体(达雷妥尤单抗、伊沙妥昔单抗、felzartamab)在IgA肾病、原发性膜性肾病及肾移植等领域的现有临床证据,同时比较其在本体肾病与抗体介导排斥反应中的不同角色。

要点

  • 抗CD38单抗可靶向长寿命浆细胞、记忆B细胞及固有效应细胞,弥补利妥昔单抗等B细胞清除疗法的不足。
  • 早期临床经验与试验数据提示抗CD38单抗在IgA肾病、原发性膜性肾病及肾移植中可能使特定患者获益。
  • 抗CD38单抗在本体肾病与抗体介导排斥反应中的机制、证据和治疗选择存在差异,需区别评估。

核心结论

  • 抗CD38单克隆抗体通过靶向利妥昔单抗等药物未能覆盖的致病性免疫细胞群,在部分肾脏疾病中显示出潜在治疗价值。

研究设计与样本

  • 叙述性综述,总结CD38表达免疫细胞在肾脏疾病中的病理生理作用,并批判性评估抗CD38单克隆抗体的现有临床证据。

主要发现

  • 利妥昔单抗或奥妥珠单抗的B细胞清除疗法不覆盖长寿命浆细胞、记忆B细胞和固有效应细胞,导致抗体持续产生和组织损伤持续。
  • 达雷妥尤单抗、伊沙妥昔单抗和felzartamab等抗CD38单抗可靶向上述多种致病性免疫细胞群。
  • 在IgA肾病、原发性膜性肾病及肾移植(尤其突出)中,早期临床经验和新兴试验数据提示抗CD38单抗在特定情形下可能获益。

临床怎么用

  • 在利妥昔单抗或奥妥珠单抗疗效不足的免疫介导肾脏疾病中,可关注抗CD38单抗作为潜在治疗选择。
  • 应用抗CD38单抗时需区分本体肾病与抗体介导排斥反应,因两者机制、临床证据和治疗选择不同。

局限性

  • 本文为叙述性综述,所依据的早期临床经验和新兴试验数据尚不足以确立抗CD38单抗在肾脏疾病中的标准治疗地位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past decades, the therapeutic landscape of nephrology has been transformed by the expanding use of immunosuppressive therapies, reflecting major advances in our understanding of the roles of the innate and adaptive immune systems in the pathogenesis of kidney diseases. While B-cell depletion via rituximab or obinutuzumab has improved immune-mediated kidney disease management, these agents remain insufficient. They spare long-lived plasma cells, memory B cells, and innate effectors, permitting persistent antibody production and ongoing tissue injury. Consequently, increasing attention has focused on anti-CD38 monoclonal antibodies, including daratumumab, isatuximab, and felzartamab, which target several of these pathogenic immune cell populations. Early clinical experience and emerging trial data in diseases such as IgA nephropathy, primary membranous nephropathy, and, most notably, kidney transplantation have suggested potential benefits in selected settings, further supporting their potential role in nephrology. In this narrative review, we summarize the current understanding of the pathophysiological role of CD38-expressing immune cells in kidney diseases and critically evaluate the available clinical evidence on the use of anti-CD38 monoclonal antibody therapies across a spectrum of renal disorders. The review also compares the roles of anti-CD38 monoclonal therapies in native kidney disease and antibody-mediated rejection, since they differ in mechanism, clinical evidence, and treatment options.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kanbay M, Copur S, Gulmaliyev I, et al. Anti-CD38 monoclonal antibodies in kidney disease: mechanistic rationale and emerging clinical evidence. Nephrol Dial Transplant. 2026. PMID: 42878696. doi:10.1093/ndt/gfag238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。